Published in Clin Cancer Res on December 01, 2001
Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer (2009) 3.99
A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer (2004) 2.01
Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines. PLoS One (2013) 1.48
Gene-nutrient interactions among determinants of folate and one-carbon metabolism on the risk of non-Hodgkin lymphoma: NCI-SEER case-control study. Blood (2007) 1.30
Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer (2009) 1.13
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer (2010) 1.10
The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol (2006) 1.06
Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. Br J Cancer (2004) 1.06
Thymidylate synthase pharmacogenetics. Invest New Drugs (2005) 1.05
A common insertion/deletion polymorphism of the thymidylate synthase (TYMS) gene is a determinant of red blood cell folate and homocysteine concentrations. Hum Genet (2005) 0.99
ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary study. BMC Cancer (2008) 0.98
High-throughput analysis of human cytomegalovirus genome diversity highlights the widespread occurrence of gene-disrupting mutations and pervasive recombination. J Virol (2015) 0.98
Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review. BMC Gastroenterol (2012) 0.95
Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. Br J Cancer (2011) 0.94
Reexamining a proposal: thymidylate synthase 5'-untranslated region as a regulator of translation efficiency. Cancer Biol Ther (2011) 0.91
Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level? Eur J Clin Pharmacol (2013) 0.85
Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy. Antimicrob Agents Chemother (2011) 0.84
Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil. J Cancer Res Clin Oncol (2010) 0.83
Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis. Pharmacogenomics (2010) 0.83
DPYD, TYMS, TYMP, TK1, and TK2 genetic expressions as response markers in locally advanced rectal cancer patients treated with fluoropyrimidine-based chemoradiotherapy. Biomed Res Int (2013) 0.83
Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) (2013) 0.81
Role of one-carbon metabolizing pathway genes and gene-nutrient interaction in the risk of non-Hodgkin lymphoma. Cancer Causes Control (2013) 0.80
Polymorphism in one-carbon metabolism pathway affects survival of gastric cancer patients: Large and comprehensive study. Oncotarget (2015) 0.80
Pharmacogenomics in chemotherapy for GI tract cancer. J Gastroenterol (2009) 0.79
Polymorphism of thymidylate synthase gene associated with its protein expression in human colon cancer. World J Gastroenterol (2008) 0.77
The effects of genomic polymorphisms in one-carbon metabolism pathways on survival of gastric cancer patients received fluorouracil-based adjuvant therapy. Sci Rep (2016) 0.76
Thymidylate synthase polymorphisms and risk of conotruncal heart defects. Am J Med Genet A (2012) 0.76
Treatment of pancreatic cancer: what can we really predict today? Cancers (Basel) (2011) 0.76
Loss of heterozygosity at thymidylate synthase locus in Barrett's metaplasia, dysplasia, and carcinoma sequences. BMC Cancer (2009) 0.75
Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. PLoS One (2014) 0.75
Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours. Sci Rep (2016) 0.75
Delimiting Allelic Imbalance of TYMS by Allele-Specific Analysis. Medicine (Baltimore) (2015) 0.75
Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer. World J Gastroenterol (2017) 0.75
Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. Pharmacogenomics J (2016) 0.75
MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res (2000) 9.30
Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem (1995) 6.25
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
p140mDia, a mammalian homolog of Drosophila diaphanous, is a target protein for Rho small GTPase and is a ligand for profilin. EMBO J (1997) 5.03
CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res (1999) 3.66
Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res (2000) 3.42
Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res (1995) 3.04
Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the rho-binding domain. J Biol Chem (1996) 2.92
ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol (2001) 2.87
Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res (2000) 2.73
A novel partner for the GTP-bound forms of rho and rac. FEBS Lett (1995) 2.52
Overexpression of the rhoC gene correlates with progression of ductal adenocarcinoma of the pancreas. Br J Cancer (1998) 2.48
Idiopathic transverse myelitis: MR characteristics. AJNR Am J Neuroradiol (1996) 2.48
Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta (1977) 2.48
Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol (2000) 2.47
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol (2006) 2.34
Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res (2001) 2.28
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol (1998) 2.26
Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J (1998) 2.23
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol (1996) 2.21
Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol (1997) 2.19
Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem (1999) 2.00
An activator binding module of yeast RNA polymerase II holoenzyme. Mol Cell Biol (1999) 2.00
Report on national surveys of cytologic facilities. CA Cancer J Clin (1971) 1.94
The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics (1995) 1.93
Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res (1999) 1.91
NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res (1992) 1.91
Graft-versus-host reactions across different regions of the H-2 complex of the mouse. J Exp Med (1973) 1.87
Duodenal somatostatinoma: a case report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Int (2000) 1.70
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res (1998) 1.68
Myxoid liposarcoma: appearance at MR imaging with histologic correlation. Radiographics (2000) 1.67
Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg (2000) 1.59
Low chloride stimulation of prostaglandin E2 release and cyclooxygenase-2 expression in a mouse macula densa cell line. J Biol Chem (2000) 1.57
Lobar bronchioloalveolar carcinoma: "angiogram sign" on CT scans. Radiology (1990) 1.55
Fluorinated pyrimidines and their nucleosides. Adv Enzymol Relat Areas Mol Biol (1983) 1.54
Lack of association between vitamin D receptor genotypes and osteoporosis in Koreans. J Clin Endocrinol Metab (1995) 1.54
Three-dimensional monitor in endoscopic surgery. Surg Endosc (2004) 1.51
Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2'-deoxyuridylate. Biochem Biophys Res Commun (1972) 1.50
[18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol (2010) 1.49
Subcutaneous and musculoskeletal sparganosis: imaging characteristics and pathologic correlation. Skeletal Radiol (2000) 1.48
Phenylpropanolamine contained in cold remedies and risk of hemorrhagic stroke. Neurology (2007) 1.47
Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res (1998) 1.46
Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst (2000) 1.45
Granulomatous mastitis: mammographic and sonographic appearances. AJR Am J Roentgenol (1999) 1.45
Bronchial sleeve resection with complete preservation of the lung for carcinoma. Respiration (2001) 1.44
Report on a national survey of cytologic facilities. CA Cancer J Clin (1965) 1.44
Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res (2000) 1.40
Long-term outcome of operative treatment of focal atrial tachycardia. J Am Coll Surg (1995) 1.39
DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer (2006) 1.36
Experimental study on heat production by a 23.5-kHz ultrasonically activated device for endoscopic surgery. Surg Endosc (1999) 1.36
p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res (1998) 1.32
Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer (1993) 1.30
Monotypic epithelioid angiomyolipoma of the liver. Histopathology (2000) 1.29
Molecular biology of esophageal cancer. Onkologie (2004) 1.28
Breast cancer susceptibility gene 1 (BRCAI) is a coactivator of the androgen receptor. Cancer Res (2000) 1.27
Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res (1992) 1.27
Fibrous dysplasia: MR imaging characteristics with radiopathologic correlation. AJR Am J Roentgenol (1996) 1.27
Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett (2000) 1.26
A case of endobronchial aspergilloma. Yonsei Med J (2000) 1.23
Metastatic tumors to the breast: mammographic and ultrasonographic findings. J Ultrasound Med (2000) 1.21
Different regions of Rho determine Rho-selective binding of different classes of Rho target molecules. J Biol Chem (1998) 1.21
Incidence of Haemophilus influenzae type b and other invasive diseases in South Korean children. Vaccine (2004) 1.20
Management of the pancreatic metastases from renal cell carcinoma: report of four resected cases. Hepatogastroenterology (1998) 1.20
Beating-heart endoscopic coronary artery surgery. Lancet (2000) 1.18
Effect of 5-fluoro- and 5-bromouracil substitution on the translation of human thymidylate synthase mRNA. J Biol Chem (1994) 1.18
Neural network modeling for on-line estimation of nutrient dynamics in a sequentially-operated batch reactor. J Biotechnol (1999) 1.17
Peroxiredoxin I expression in human thyroid tumors. Cancer Lett (1999) 1.17
Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene (2001) 1.17
Intratendinous ganglion cyst of the semimembranosus tendon. Br J Radiol (2010) 1.16
The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer (2001) 1.16
Gender differences in three dimensional gait analysis data from 98 healthy Korean adults. Clin Biomech (Bristol, Avon) (2004) 1.15
Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites. Clin Colorectal Cancer (2001) 1.14
Concomitant duodenal and pancreatic metastases from renal cell carcinoma: report of a case. Surg Today (2001) 1.13